SSG
TARS icon

Summit Securities Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Summit Securities Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-157
Closed -$8.69K – 1092
2024
Q4 		$8.69K Buy
+157
New +$7.13K ﹤0.01% 478

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Summit Securities Group's TARS Position: Q1 2025 in Review

Summit Securities Group sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 157 shares — an estimated $8.69K sold.

Summit Securities Group first reported a position in TARS in Q4 2024 and held it in 1 quarter. The position peaked at $8.69K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

  • Summit Securities Group reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Summit Securities Group sold 157 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $8.69K.
  • Summit Securities Group first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Summit Securities Group's Tarsus Pharmaceuticals position peaked at $8.69K in Q4 2024.
  • 194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Summit Securities Group's 13F filing for Q1 2025, filed 13 May 2025.